top of page
eracal closes this gap by developing potent and highly selective appetite suppressants, with animal models showing superior effectiveness at reducing weight over current drugs on the market. eracal was spun out of the university of zurich and harvard university in 2018.
potent, effective appetite suppressants
obesity is one of the most widespread diseases of the 21st century and comes with a high risk of cardiovascular disease, type 2 diabetes, cancer, and reduced life expectancy. treating obesity with drugs has, so far, not been effective, often resulting in unwanted side effects and failing to prevent the onset of obesity-associated complications.
preventing the onset of obesity-related diseases
rac IV
healthtech
2019
2017
fund
sector
invested in
founded
bottom of page